Clinical prognostic factors for fibrolamellar liver carcinoma

Autor: Elena Yu. Antonova, Ekaterina A Moroz, Daniil V. Podlyzny, Nikolai E. Kudashkin, Aleksandr Yu. Volkov, Irina A. Dzhanyan, Konstantin K. Laktionov, Valery V. Breder

Publikováno v: Russian Journal of Oncology. 26:13-22

BACKGROUND: Fibrolamellar liver carcinoma is a rare subtype of liver cancer with an unexplored etiology. There is no information about the choice of classification for fibrolamellar liver carcinoma (FLC) in the world literature, and data on the progn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19888b4cc8081074aa1c22715fe4c032
https://doi.org/10.17816/1028-9984-2021-26-1-13-22

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.

Autor: Yau T; Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. Electronic address: tyaucc@hku.hk., Kaseb A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cheng AL; National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan., Qin S; Cancer Center of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China., Zhu AX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China., Chan SL; State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China., Melkadze T; Ltd Academician Fridon Todua Medical Center-Ltd Research Institute of Clinical Medicine, Tbilisi, Georgia., Sukeepaisarnjaroen W; Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand., Breder V; FSBSI N Blokhin Russian Cancer Research Center, Moscow, Russia., Verset G; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium., Gane E; New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand and Department of Medicine, University of Auckland, Auckland, New Zealand., Borbath I; Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium., Rangel JDG; Department of Medical Oncology, Centro Oncologico de Veracruz, CLIMERS, Veracruz, Mexico., Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Makharadze T; Ltd High Technology Hospital Medcenter, Batumi, Adjara, Georgia., Merle P; Hepatology Unit, Hôpital de la Croix-Rousse, Groupement Hospitalier Lyon Nord, Lyon, France., Benzaghou F; Ipsen Bioscience, Cambridge, MA, USA., Milwee S; Exelixis, Alameda, CA, USA., Wang Z; Exelixis, Alameda, CA, USA., Curran D; Exelixis, Alameda, CA, USA., Kelley RK; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Rimassa L; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Publikováno v: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2024 Apr; Vol. 9 (4), pp. 310-322. Date of Electronic Publication: 2024 Feb 13.

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.

Autor: Vogel A; Hannover Medical School, Hannover, Germany. Electronic address: vogel.arndt@mh-hannover.de., Qin S; Nanjing Bayi Hospital, Nanjing, Jiangsu, China., Kudo M; Kindai University Faculty of Medicine, Osaka, Japan., Su Y; Eisai, Woodcliff Lake, NJ, USA., Hudgens S; Clinical Outcome Solutions, Tucson, AZ, USA., Yamashita T; Kanazawa University Hospital, Kanazawa, Japan., Yoon JH; Seoul National University Hospital, Seoul, South Korea., Fartoux L; Hôpital Saint Joseph, Paris, France., Simon K; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland., López C; Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain., Sung M; Tisch Cancer Institute at Mount Sinai, New York, NY, USA., Mody K; Eisai, Woodcliff Lake, NJ, USA., Ohtsuka T; Eisai, Woodcliff Lake, NJ, USA., Tamai T; Eisai, Woodcliff Lake, NJ, USA., Bennett L; RTI Health Solutions, Durham, NC, USA., Meier G; Eisai, Woodcliff Lake, NJ, USA., Breder V; FSBSI N N Blokhin Russian Cancer Research Center, Moscow, Russia.

Publikováno v: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Aug; Vol. 6 (8), pp. 649-658. Date of Electronic Publication: 2021 Jun 02.

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.

Autor: Thatcher N; The Christie Hospital, Manchester, United Kingdom. Nick.Thatcher@christie.nhs.uk., Goldschmidt JH; Oncology and Hematology Associates of Southwest Virginia, US Oncology Research, McKesson Specialty Health, Blacksburg, Virginia., Thomas M; Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitatsklinikum, Heidelberg, Translational Lung Research Center, Heidelberg, Germany., Schenker M; Centrul de Oncologie Sf Nectarie, Craiova, Romania., Pan Z; Amgen Inc., Thousand Oaks, California., Paz-Ares Rodriguez L; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain., Breder V; Department of Clinical Biotechnologies, N. N. Blokhin National Medical Research Center of Oncology, Russia., Ostoros G; Koranyi National Institute for TB and Pulmonology, Budapest, Hungary., Hanes V; Amgen Inc., Thousand Oaks, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Apr 01; Vol. 25 (7), pp. 2088-2095. Date of Electronic Publication: 2019 Jan 07.

Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.

Autor: Ivanov M; Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow Region, 141700, Russia.; Atlas Biomed Group, Moscow, 121069, Russia.; Institute of Chemical Biology and Fundamental Medicine of SB RAS, Novosibirsk, 630090, Russia., Laktionov K; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia., Breder V; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia., Chernenko P; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia., Novikova E; Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology), Moscow, 117485, Russia., Telysheva E; Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology), Moscow, 117485, Russia., Musienko S; Atlas Biomed Group, Moscow, 121069, Russia., Baranova A; Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow Region, 141700, Russia. abaranov@gmu.edu.; Atlas Biomed Group, Moscow, 121069, Russia. abaranov@gmu.edu.; Research Centre for Medical Genetics, Moscow, 115478, Russia. abaranov@gmu.edu.; Center for the Study of Chronic Metabolic and Rare Diseases, School of System Biology, George Mason University, Fairfax, VA, USA. abaranov@gmu.edu., Mileyko V; Atlas Biomed Group, Moscow, 121069, Russia.; Institute of Chemical Biology and Fundamental Medicine of SB RAS, Novosibirsk, 630090, Russia.

Publikováno v: Journal of translational medicine [J Transl Med] 2017 Jan 31; Vol. 15 (1), pp. 22. Date of Electronic Publication: 2017 Jan 31.